Angiographic and Clinical Outcomes After Treatment of Femoro-Popliteal Lesions with a Novel Paclitaxel-Matrix-Coated Balloon Catheter

[1]  S. Spiliopoulos,et al.  Comparative Effectiveness of Plain Balloon Angioplasty, Bare Metal Stents, Drug-Coated Balloons, and Drug-Eluting Stents for the Treatment of Infrapopliteal Artery Disease , 2016, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[2]  W. Guo,et al.  Acotec Drug-Coated Balloon Catheter: Randomized, Multicenter, Controlled Clinical Study in Femoropopliteal Arteries: Evidence From the AcoArt I Trial. , 2016, JACC. Cardiovascular interventions.

[3]  A. Kastrati,et al.  Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials. , 2016, JACC. Cardiovascular interventions.

[4]  S. Spiliopoulos,et al.  Systematic Review and Meta-analysis of Randomized Controlled Trials of Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Arteries , 2016, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[5]  Hong Wang,et al.  Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA. , 2015, Journal of the American College of Cardiology.

[6]  D. Scheinert,et al.  Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. , 2015, The New England journal of medicine.

[7]  S. Duda,et al.  Two‐year results of a low‐dose drug‐coated balloon for revascularization of the femoropopliteal artery: Outcomes from the ILLUMENATE first‐in‐human study , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[8]  D. Scheinert,et al.  Paclitaxel-Releasing Balloon in Femoropopliteal Lesions Using a BTHC Excipient , 2015, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[9]  Igor Rudan,et al.  Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis , 2013, The Lancet.

[10]  T. Albrecht,et al.  Paclitaxel-Coated Balloons Reduce Restenosis After Femoro-Popliteal Angioplasty: Evidence From the Randomized PACIFIER Trial , 2012, Circulation. Cardiovascular interventions.

[11]  E. Minar,et al.  Claudication: treatment options for femoropopliteal disease. , 2011, Progress in cardiovascular diseases.

[12]  Harald Darius,et al.  Mortality and Vascular Morbidity in Older Adults With Asymptomatic Versus Symptomatic Peripheral Artery Disease , 2009, Circulation.

[13]  B. Hamm,et al.  Inhibition of Restenosis in Femoropopliteal Arteries: Paclitaxel-Coated Versus Uncoated Balloon: Femoral Paclitaxel Randomized Pilot Trial , 2008, Circulation.

[14]  C. Claussen,et al.  Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. , 2008, The New England journal of medicine.

[15]  M. Böhm,et al.  Reduction of Stenosis Due to Intimal Hyperplasia After Stent Supported Angioplasty of Peripheral Arteries by Local Administration of Paclitaxel in Swine , 2007, Investigative radiology.

[16]  C. Claussen,et al.  Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. , 2015, JACC. Cardiovascular interventions.

[17]  M. Joner,et al.  Drug-coated balloon therapy in coronary and peripheral artery disease , 2014, Nature Reviews Cardiology.

[18]  D. Scheinert,et al.  The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. , 2014, JACC. Cardiovascular interventions.